Skip to main content

Drug Interactions between deutetrabenazine and methylene blue

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

methylene blue deutetrabenazine

Applies to: methylene blue and deutetrabenazine

CONTRAINDICATED: Tetrabenazine may cause excitation and hypertension in patients treated with monoamine oxidase inhibitors (MAOIs). The proposed mechanism has not been fully established but may be related to interference with biogenic amine storage. In addition, tetrabenazine may have depressant effects and may exacerbate depression. The same interaction can be expected for deutetrabenazine, a deuterium-containing analog of tetrabenazine.

MANAGEMENT: Concurrent administration of tetrabenazine and deutetrabenazine with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with either tetrabenazine or deutetrabenazine, and vice versa.

References (3)
  1. (2003) "Product Information. Nitoman (tetrabenazine)." Cambridge Laboratories Ltd
  2. (2008) "Product Information. Xenazine (tetrabenazine)." Prestwick Pharmaceuticals Inc
  3. (2017) "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer